Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death in the United States ([@bib1]). Much attention has been focused on coffee and tea consumption and CRC because these beverages are widely consumed and are rich sources of anticancer components. Numerous *in vitro* and *in vivo* studies have suggested that coffee constituents, such as caffeine and chlorogenic acid, have a role in reducing colonic tumor formation ([@bib17]; [@bib2]; [@bib14]; [@bib3]). Similarly, (−)-epigallocatechin-3-gallate (EGCG), the major catechin found in green tea and black tea polyphenols have been shown to have chemoprotective properties in *in vitro* and in *in vivo* studies ([@bib43]; [@bib27]; [@bib24]; [@bib28]; [@bib33]).

The relationship of coffee and tea consumption to CRC has been examined in previous epidemiologic studies with inconsistent findings. Most case--control studies have reported an inverse relationship of coffee and tea consumption to CRC ([@bib7]; [@bib16]). Recently, a large cohort study has also reported an inverse association of coffee with CRC ([@bib30]). However, most cohort studies have reported a null association between coffee and CRC risk ([@bib13]; [@bib16]). For tea, results have also been inconsistent across various studies ([@bib35]).

We conducted a prospective cohort study to examine the relationship of coffee and tea intake with the risk of CRC in 57 398 men and women in the National Cancer Institute-Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial ([@bib25]), a national screening-based study that limits biases due to differential detection of cancers. Subjects in our study were randomised to flexible sigmoidoscopy screening and were subsequently followed to examine the relationship of coffee and tea consumption to CRC risk, overall and by tumor site and stage.

Subjects and methods
====================

Study population
----------------

The PLCO Cancer Screening Trial is a multicentre trial designed to evaluate screening methods for the early detection of several cancers ([@bib40]). Briefly, 154 900 men and women, aged 55--74 years, were recruited from 10 centres (Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfield, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St Louis, MO; and Washington, DC, USA) between 1993 and 2001 and randomised to receive either CRC screening (sigmoidoscopy, insertion to at least 50 cm with \>90% of mucosa visible or a suspect lesion identified) or standard care. Participants completed baseline and diet questionnaires. The study was approved by the institutional review boards at the National Cancer Institute and the screening centres, and all participants provided informed consent.

Of the 75 187 men and women who were randomly assigned to the intervention arm of the trial, 58 449 participants (78%) completed both the baseline risk factor and food frequency (\<8 questions missing) questionnaires. We further excluded 1051 participants for the following reasons: a missing response for coffee intake (*n*=195); previous history of cancer, except basal-cell skin cancer (*n*=2758); or self-reported history of ulcerative colitis, Crohn\'s disease, familial polyposis or Gardner\'s syndrome (*n*=1140). After exclusions, the analytic cohort comprised 57 398 subjects (some participants were in more than one exclusion category). Within this cohort, 47 678 (83%) received a complete flexible sigmoidoscopy screening at baseline.

Colorectal cancer ascertainment
-------------------------------

As part of the CRC screening portion of the PLCO trial, flexible sigmoidoscopic visualisation of the distal colon was carried out at baseline and then again at 3 or 5 years (protocol changed from rescreening at 3 years to 5 years in April 1995). Those who had suspected lesions for colorectal neoplasia (i.e., sigmoidoscopically visualised polypoid lesions or masses) were referred to their health-care providers for endoscopic and histopathologic follow-up. Subjects were also sent annual questionnaires asking about recent cancer diagnoses. The PLCO trial obtained all available medical and pathological reports on all lesions removed during the diagnostic endoscopy and related surgical procedures for all subjects with an abnormal sigmoidoscopic examination, or all colorectal cancers reported on the questionnaires or through death certificates. This information was abstracted and coded by trained medical abstractors. Only histologically confirmed cases were included in the analysis.

Coffee and tea intake
---------------------

At study baseline, participants completed a Baseline Questionnaire on sociodemographics, smoking status, lifestyle factors, and personal and family medical history. Dietary intake was assessed by a Dietary Questionnaire (DQX) given at baseline. This food frequency questionnaire included 137 individual food items, 77 of which queried about usual portion size and frequency (<https://www.plcostars.com/Public/Documents/PLCO/DQX.pdf>). The DQX was designed on two previously validated food frequency questionnaires ([@bib42]; [@bib4]). Nutrient and food group values were calculated by the method developed by Subar and co-workers ([@bib32]), using US dietary data and the pyramid food group servings database from the [@bib38]. The categorical groupings of the coffee and tea variables were derived from the combination of the number of servings and serving size. In addition, caffeinated and decaffeinated coffee intake was assessed by a second dietary questionnaire, the NIH Health Diet History Questionnaire (DHQ) (<https://www.plcostars.com/Public/Documents/PLCO/DHQ.pdf>), which was administered to screening arm subjects in about the third year of follow-up, beginning in December 1998. The correlations between the two diet questionnaires were *r*=0.63 and 0.61 for coffee and tea intakes, respectively. Coffee intake was assigned into one of five categories for each questionnaire: none (reference group), \<1 cup per day, 1 cup per day, 2--3 cups per day and **⩾**4 cups per day. Tea intake was assigned to one of four categories: none (reference group), \<1 cup per week, 1 cup per day and **⩾**2 cups per day.

Statistical analysis
--------------------

We estimated relative risks (RRs) and 95% confidence intervals (CIs) with Cox proportional hazards models ([@bib6]). We calculated person-years of follow-up time from the date of the baseline DQX until the date of CRC diagnosis, death or end of follow-up, whichever occurred first. We confirmed that the proportional hazard assumption was met for the main exposures by visualisation of Schoenfeld residuals\' plots. Multivariable analyses were adjusted for potentially confounding factors, including age (continuous), gender (male, female), race (White, Black, Asian, other), PLCO study centre, family history of CRC (first degree; yes, no), smoking status (never, current, former, pipe/cigar only), education (\<12 years, 12 years of high school, post high school or college, and college graduation or more), history of diabetes (yes, no), body mass index (BMI) (18.5--24.9, 25.0--29.9 and 30.0 kg m^−2^ or more), number of screenings 3 years before the trial (none, once and more than once), physical activity (none, \<1, 1, 2, 3 and 4+ h per week), non-steroidal anti-inflammatory drug intake (none, aspirin only, ibuprofen only, both aspirin and ibuprofen), hormone status among women (never, former and current), meat intake (g per day), fruit intake (servings per day), vegetable intake (servings per day) and alcohol intake (g per day). Further adjustment of total energy intake did not significantly modify risk estimates, so it was not included in analyses. Missing values were generally imputed into the most common category. To control for any confounding effect that tea might have on coffee or *vice versa*, tea and coffee variables were additionally included in the respective models. Tests for linear trends were conducted by assigning the median value for each category and treating that term as a single continuous variable in the model. In a subanalysis, we excluded the first 3 years of follow-up to minimse effects of preclinical disease. To reduce the effect of flexible sigmoidoscopy screening, analyses were also carried out in only those who received screening at baseline. Stratified analyses were carried out to examine possible interactions between coffee or tea and the key risk factors of age, gender, smoking status, BMI, meat intake and alcohol intake. We formally tested for interactions using log-likelihood ratio tests. All statistical tests were two-sided and considered significant at *P*\<0.05.

As a subanalysis, caffeinated and decaffeinated coffee analyses were carried out in subsets of participants who had completed coffee-related questions in the additional DHQ questionnaire. Caffeinated coffee intake was defined as those who only consumed caffeinated coffee (*n*=29 099) and decaffeinated coffee intake was defined as those who only consumed decaffeinated coffee (*n*=18 262). Those who consumed both caffeinated and decaffeinated coffees were not included in either analysis. Person-years of follow-up time were calculated from the date of completing the DHQ until the date of CRC diagnosis, death or end of follow-up, whichever occurred first. All analyses for the DQX and DHQ were carried out using SAS, version 9.3 (SAS Institute, Cary, NC, USA).

Results
=======

Baseline characteristics
------------------------

During the median follow-up time of 11.4 years, 587 683 person-years were accumulated and 681 incident CRC cases were identified, including 381 proximal and 148 distal colon cancers and 142 rectal cancers. By stage, 235 cases were diagnosed as stage I, 161 cases were diagnosed as stage II and 249 cases were diagnosed as advanced (stage III/IV).

Eighty-eight percent of the population consumed coffee; the overall median coffee consumption was 1 cup per day. Greater coffee consumption was related to being male, a current smoker, being less physically active, a more frequent consumer of aspirin, meat and alcohol and a less frequent consumer of fruits and vegetables ([Table 1](#tbl1){ref-type="table"}). Among women, greater coffee consumption was related to less use of postmenopausal hormones. Greater tea consumers were more likely to be women, use aspirin less and consume more fruits and vegetables but less alcohol. Among women, higher tea consumers were more likely to have used postmenopausal hormones.

Coffee intake and colorectal cancer risk
----------------------------------------

In the age-adjusted model, greater coffee intake was not associated with risk of CRC ([Table 2](#tbl2){ref-type="table"}). The association remained unchanged after adjusting for non-dietary risk factors and in the final full model, which further adjusted for meat, fruit and vegetable intake, the association remained null (RR for **⩾**4 cups per day *vs* none=1.08, 95% CI=0.79--1.48, *P*~trend~=0.23). In addition, adjusting for tea intake also did not affect the association (RR=1.06, 95% CI=0.77--1.46, *P*~trend~=0.26). When we excluded the first 3 years of follow-up, this relationship remained unchanged (RR=1.09, 95% CI=0.72--1.64, *P*~trend~=0.75). Excluding participants who did not receive complete flexible sigmoidoscopy screening also did not alter the relationship (RR=1.09, 95% CI=0.78--1.54, *P*~trend~=0.19). Both caffeinated and decaffeinated coffees were not associated with CRC risk (for caffeinated coffee: RR=1.08, 95% CI=0.67--1.75; for decaffeinated coffee: RR=1.53, 95% CI=0.75--3.09). Restricting the analysis to individuals who had the same responses in both the baseline DQX and the follow-up DHQ did not alter the relationship between coffee and CRC risk (data not shown).

These associations were consistently null by cancer site (for proximal: RR=1.33, 95% CI=0.86--2.05; for distal: RR=1.11, 95% CI=0.58--2.13; and for rectal: RR=0.72, 95% CI=0.36--1.44; *P* for heterogeneity=0.48) and stage (I/II and III/IV, *P* for heterogeneity=0.83) ([Table 2](#tbl2){ref-type="table"}). Limiting our analysis to the 93.1% colorectal adenocarcinoma cases did not alter the relationship of coffee intake and CRC risk. The association between coffee intake and risk of CRC was not significantly modified by gender (*P* for interaction=0.57) or age at baseline (*P* for interaction=0.25). We also found no statistically significant differences in the association between coffee and CRC risk by BMI (*P* for interaction=0.87), smoking status (*P* for interaction=0.64), alcohol consumption (*P* for interaction=0.62) or meat intake (*P* for interaction=0.30).

Tea intake and colorectal cancer risk
-------------------------------------

As shown in [Table 3](#tbl3){ref-type="table"}, there was a significant inverse association between the highest quartile of tea intake and CRC risk (RR=0.66, 95% CI=0.47--0.92, *P*~trend~=0.02) in the age-adjusted model; however, the association was not statistically significant after adjusting for non-dietary factors and after full adjustment (RR=0.77, 95% CI=0.55--1.09, *P*~trend~=0.17). Additionally, including coffee intake into the model did not change the relationship (RR=0.78, 95% CI=0.55--1.11, *P*~trend~=0.19). Further excluding the first 3 years of follow-up did not affect the relationship (RR=0.85, 95% CI=0.55--1.31, *P*~trend~=0.81). The association remained nonsignificant after exclusion of participants who did not receive complete flexible sigmoidoscopy (RR=0.83, 95% CI=0.56--1.21, *P*~trend~=0.28).

As with coffee, subanalysis by cancer site (proximal, distal and rectal, *P* for heterogeneity=0.14) and stage (I/II, III/IV, *P* for heterogeneity=0.60) did not reveal significant associations between tea and CRC risk ([Table 3](#tbl3){ref-type="table"}). The association remained null with the analysis of adenocarcinoma cases only (93.1%). Similar nonsignificant associations were observed for men and women (*P* for interaction=0.99) and for younger (⩽62 years) and older participants (\>62 years; *P* for interaction=0.68). There were also no statistically significant effect modifications between tea and CRC risk by body mass index (*P* for interaction=0.28), smoking status (*P* for interaction=0.94), alcohol consumption (*P* for interaction=0.72) or meat intake (*P* for interaction=0.64).

Discussion
==========

In this large prospective study from a CRC screening trial, we found that greater coffee and tea intakes were not associated with risk of colorectal cancer. These findings were consistent for coffee with and without caffeine and for tea irrespective of cancer site and stage or selected demographic and risk factors.

Studies of coffee intake with CRC risk are inconclusive. For the most part, significant inverse associations have been reported in case--control studies. A recent, meta-analysis of 25 case--control studies comparing the highest category of coffee intake to the none/lowest intake category reported RRs of 0.85 (95% CI=0.75--0.97) for CRC ([@bib16]). However, these case--control studies are prone to recall bias related to dietary intake since diet intake assessment was carried out after cancer diagnosis. It is also possible that after cancer diagnosis, coffee or tea drinking habits could have changed.

Recently, the NIH-AARP Diet and Health Study, a very large cohort study of older adults (6946 cases), showed significant inverse associations between coffee and CRC risk (RR=0.80, 95% CI=0.69--0.94) ([@bib30]), due largely to an inverse relationship for proximal tumors (RR=0.62, 95% CI=0.49--0.81). Contrary to these findings, most cohort studies have reported null associations of coffee and risk of CRC, consistent with our findings. An analysis of comparable size, the Pooling Project of Prospective Studies of Diet and Cancer, which pooled data from 13 studies, reported a null association for their highest category of coffee intake and colon cancer (RR=1.07, 95% CI=0.89--1.30) ([@bib46]). Also, the Pooling Project noted no risk differentials by cancer site (proximal and distal colon cancers). A 2012 meta-analysis of 16 cohort studies (10 443 cases) reported no significant association between coffee consumption and CRC risk (RR=0.94, 95% CI=0.88--1.01) ([@bib16]).

Most significant, inverse associations in cohort studies have been observed in subgroup analyses (typically by gender or age). The two studies that have reported significant inverse associations in women were carried out in Japanese populations ([@bib23]; [@bib15]), whereas a study on a Norwegian population (mostly men) only observed a statistically significant association among men younger than 65 years ([@bib12]). This study explored potential interactions by stratifying the cohort by several demographic and risk factors, resulting in no significant differences.

Limiting the analyses to either caffeinated or decaffeinated coffee drinkers did not alter the associations observed in the main analysis. In the United States, pooled analysis of the Nurses\' Health Study and Health Professionals\' Follow-Up Study also resulted in null associations for caffeinated coffee. Using 5+ cups per day as the highest grouping of coffee intake, the RR (95% CI) for CRC was 0.98 (0.69--1.38) ([@bib18]). However, they did report a significant, inverse association between decaffeinated coffee and rectal cancer (RR=0.48, 95% CI=0.29--0.81). In this study, decaffeinated coffee was not associated with overall CRC risk and the fairly small number of rectal cases did not permit further subset analysis for decaffeinated coffee drinkers.

Ten cohort studies ([@bib8]; [@bib47]; [@bib21]; [@bib20]; [@bib37]; [@bib18]; [@bib36]; [@bib34]; [@bib29]; [@bib30]) have reported null associations between tea (green, black or unspecified) and CRC risk. A meta-analysis ([@bib35]) of black tea studies reported a combined RR of 1.02 (95% CI=0.78--1.24), whereas a meta-analysis ([@bib39]) of green tea studies reported a combined RR of 0.90 (95% CI=0.72--1.08).

In contrast, a handful of cohort studies have generated significant inverse ([@bib31]; [@bib44], [@bib45]) or positive ([@bib10]; [@bib9]; [@bib37]; [@bib34]; [@bib46]; [@bib30]) associations between tea and total CRC risk, as well as within various subgroups. Significant, inverse associations between tea and CRC risk were reported in the Shanghai Women\'s Health Study ([@bib44]) and the Shanghai Men\'s Health Study ([@bib45]). For men, the effect was particularly profound among non-smokers for colon cancer. One possible explanation for the inconsistent findings between the Shanghai studies *vs* this study could be cultural and lifestyle differences in the type and amount of tea consumed. Both studies excluded those who drank black tea, the type of tea more commonly consumed in western countries ([@bib19]; [@bib44], [@bib45]). Although the NIH-AARP Diet and Health Study ([@bib30]) reported a null association for tea and overall CRC risk, it did find a significant, positive association with distal colon cancers. Similarly, the Pooling Project of Prospective Studies of Diet and Cancer reported a significant, positive association between tea and colon cancer ([@bib46]). However, both studies address the possibility that these findings could be due to chance.

There are several strengths of this study. First, as diet and demographic information were collected before the diagnosis of cancer in this large prospective study, differential recall bias by disease status was minimised. Second, extensive baseline and diet intake information were collected allowing for appropriate control of confounders and additional subgroup analyses. Lastly and uniquely to this study, because the majority of the cohort (83.3%) had complete flexible sigmoidoscopy CRC screening at baseline, all participants had an equal opportunity to be screened, so any screening-related biases are unlikely to be a factor in this study. However, because our study was conducted in the screening arm of a randomised controlled trial of CRC screening, results may not be generalisable to all cases.

There are several limitations to this study. An inherent limitation of dietary questionnaires is their potential for non-differential measurement error, which can bias the results towards the null ([@bib41]). Another limitation is the natural complexity of the content of coffee and tea, which is not adequately captured by current dietary assessment methods. Furthermore, neither of the dietary questionnaires distinguished between brewing methods for coffee, which may impact its anticarcinogenic effects. Brewing methods can typically be divided into two categories, boiling and filtering. There has only been one study looking at brewing method and CRC risk, and it reported null associations ([@bib22]). However, it is noteworthy that anticarcinogenic effects of coffee diterpenes have been reported ([@bib5]; [@bib11]), the major component removed by filtering ([@bib26]), which happens to be the more common of the two practices among Americans. The questionnaires also did not differentiate the type of tea consumed (black or green). As black tea is more commonly consumed among Americans, combined analysis of both types of tea might mask potential tea type-specific associations. Although the main analysis had sufficient power (minimum detectable relative risk of 0.86 for coffee and CRC), the power to detect an association in specific subgroups, such as by location (proximal, distal or rectal) or coffee type (caffeinated *vs* decaffeinated) was limited.

In conclusion, the findings of this study do not provide evidence that drinking coffee or tea is beneficial in protecting against colorectal cancer. Furthermore, the inconsistent results across all types of studies do not conclusively support the protective effects of coffee or tea against CRC and do not lead to specific recommendations for use of these beverages for CRC risk reduction.
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###### Baseline characteristics of participants from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial separated by coffee and tea intake

                                                                                   **Coffee**      **Tea**                                                                                               
  ------------------------------------------------------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  Participants (*n*)                                                                  6754          11 919         12 474         16 983          9268           9086          34 014          5063           5379
  Tea (%)                                                                             56.1           89.6           86.6           86.6           82.6           ---            ---            ---            ---
  Coffee (%)                                                                          ---            ---            ---            ---            ---            69.3            94            89.3           82.4
  Age (years, mean±s.d.)                                                           61.8±5.31      63.0±5.39      63.4±5.35      62.6±5.27      62.0±5.08      62.4±5.37      62.7±5.28      63.1±5.40      62.4±5.34
  Men (%)                                                                             41.8           53.8           49.4           52.6           56.9           58.8           53.3           41.5           37.6
  Caucasian (%)                                                                       90.9           84.8           88.7           93.8           96.1           94.4           90.2           88.9           90.9
  Family history of colorectal cancer (%)                                             9.7            10.6           10.9           10.6           9.3            10.7           10.2           10.7           10.3
  High school graduate (%)                                                            22.6           22.3           23.5           23.2           24.1           28.8           22.0           21.6           22.3
  Body mass index (kg m^−2^, mean±s.d.)                                            27.6±5.14      27.6±5.08      27.2±4.76      27.2±4.62      27.2±4.58      27.7±4.80      27.3±4.80      26.8±4.67      27.1±4.92
  Current smoker (%)                                                                  3.9            6.0            7.6            10.2           21.2           11.8           9.8            7.0            9.1
  Physical activity (**⩾**4 h per week, %)                                            24.2           24.2           24.4           22.9           20.8           23.1           23.1           24.7           24.0
  Aspirin-only intake (%)                                                             27.0           30.5           31.4           32.8           32.8           31.5           31.5           32.0           29.2
  Diabetes (%)                                                                        7.6            8.7            7.0            6.3            6.3            7.1            7.0            7.0            7.9
  Colorectal examination (none in prior 3 years, %)[a](#t1-fn1){ref-type="fn"}        94.2           80.9           85.0           84.7           85.8           92.2           82.9           86.1           87.9
  Hormone use among women (%)                                                         56.1           51.2           52.8           51.8           45.7           49.1           52.1           51.8           52.4
  Fruits (servings per day, mean±s.d.)                                              3.7±2.46       3.6±2.41       3.4±2.17       3.3±2.06       3.1±2.26       3.2±2.25       3.4±2.22       3.7±2.22       3.6±2.41
  Vegetables (servings per day, mean±s.d.)                                          5.0±2.45       5.0±2.41       5.0±2.38       5.1±2.35       5.2±2.45       4.7±2.35       5.0±2.36       5.4±2.47       5.5±2.61
  Meat (g per day, mean±s.d.)                                                     156.1±116.01   165.4±115.19   165.7±112.08   174.5±111.25   193.5±127.81   173.1±120.64   172.9±115.70   161.9±109.58   169.6±116.96
  Alcohol (g per day, mean±s.d.)                                                   4.4±16.45      8.5±19.85      12.9±24.20     12.7±24.07     13.2±28.15     11.8±28.25     11.7±23.33     8.6±18.34      7.3±18.34

Colorectal examinations included colonoscopy, sigmoidoscopy or barium enema.

###### RRs[a](#t2-fn2){ref-type="fn"} for total and subtypes of colorectal cancer by coffee intake in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

                                                                              **None**   **\<1 cup per day**   **1 cup per day**   **2--3 cups per day**   **⩾4 cups per day**                                                                           
  --------------------------------------------------------------------------- ---------- --------------------- ------------------- ----------------------- --------------------- ------------------- ----- ------------------- ----- ------------------- -------
  **Total colorectal**                                                                                                                                                                                                                                   
  Age adjusted                                                                73         1.00 (referent)       138                 0.99 (0.75, 1.32)       147                   0.98 (0.74, 1.30)   207   1.07 (0.82, 1.39)   116   1.16 (0.87, 1.55)   0.137
  Multivariate adjusted[b](#t2-fn3){ref-type="fn"}                            73         1.00 (referent)       138                 0.94 (0.70, 1.26)       147                   0.95 (0.71, 1.27)   207   1.04 (0.78, 1.38)   116   1.09 (0.80, 1.49)   0.215
  Multivariate adjusted[c](#t2-fn4){ref-type="fn"}                            73         1.00 (referent)       138                 0.94 (0.70, 1.25)       147                   0.94 (0.70, 1.26)   207   1.03 (0.77, 1.37)   116   1.08 (0.79, 1.48)   0.229
  **Histopathology[c](#t2-fn4){ref-type="fn"}[,d](#t2-fn5){ref-type="fn"}**                                                                                                                                                                              
  Adenocarcinoma                                                              70         1.00 (referent)       128                 0.91 (0.67, 1.23)       138                   0.92 (0.68, 1.25)   189   0.99 (0.74, 1.32)   109   1.08 (0.78, 1.49)   0.225
  **Topography[c](#t2-fn4){ref-type="fn"}[,e](#t2-fn6){ref-type="fn"}**                                                                                                                                                                                  
  Proximal colon                                                              35         1.00 (referent)       86                  1.19 (0.79, 1.78)       88                    1.15 (0.76, 1.74)   103   1.04 (0.69, 1.57)   69    1.33 (0.86, 2.05)   0.454
  Distal colon                                                                18         1.00 (referent)       24                  0.68 (0.36, 1.28)       33                    0.89 (0.48, 1.63)   48    1.06 (0.59, 1.89)   25    1.11 (0.58, 2.13)   0.160
  Rectum                                                                      17         1.00 (referent)       28                  0.85 (0.46, 1.59)       22                    0.62 (0.32, 1.20)   55    1.18 (0.66, 2.10)   20    0.72 (0.36, 1.44)   0.864
  **Stage[c](#t2-fn4){ref-type="fn"}[,f](#t2-fn7){ref-type="fn"}**                                                                                                                                                                                       
  I                                                                           35         1.00 (referent)       41                  0.58 (0.36, 0.92)       44                    0.58 (0.36, 0.93)   76    0.78 (0.50, 1.20)   39    0.74 (0.45, 1.22)   0.552
  II                                                                          14         1.00 (referent)       33                  1.06 (0.57, 2.02)       38                    1.12 (0.59, 2.12)   45    1.02 (0.54, 1.92)   31    1.28 (0.65, 2.50)   0.520
  III and IV                                                                  24         1.00 (referent)       57                  1.25 (0.76, 2.04)       57                    1.19 (0.72, 1.97)   70    1.16 (0.71, 1.90)   41    1.35 (0.79, 2.31)   0.508

Abbreviations: CI=confidence interval; NSAID=non-steroidal anti-inflammatory drug; RR=relative risk.

All estimated RRs and 95% CIs were computed using Cox proportional hazards regression models with person-years as the underlying time metric.

Multivariate model adjusted by age, gender, race, family history of colorectal cancer, education, body mass index (kg m^−2^), physical activity, smoking status, NSAID intake, history of diabetes, number of colorectal examinations up to 3 years before the start of study, hormone use (among women), alcohol intake (g per day) and study centre.

All multivariate models were adjusted by age, gender, race, family history of colorectal cancer, education, body mass index (kg m^−2^), physical activity, smoking status, NSAID intake, history of diabetes, number of colorectal examinations up to 3 years before the start of study, hormone use (among women), fruit intake (servings per day), vegetable intake (servings per day), meat intake (g per day), alcohol intake (g per day) and study centre. *P*-values for linear trends were calculated using the quintile median values. All statistical tests were two-sided and considered significant at *P*\<0.05. All analyses were carried out using SAS software (version 9.3).

By histopathology: 634 adenocarcinoma; 31 carcinoid; 6 squamous; 10 other cases.

By topography: ---381 proximal; 148 distal; 142 rectal; 10 unspecified cases.

By stage: 235 stage I; 161 stage II; 249 stage III/IV; 36 unspecified cases.

###### RRs[a](#t3-fn2){ref-type="fn"} for total and subtypes of colorectal cancer by tea intake in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

                                                                              **None**   **\<1 cup per day**   **1 cup per day**   **⩾2 cups per day**                                                     
  --------------------------------------------------------------------------- ---------- --------------------- ------------------- --------------------- ---- ------------------- ---- ------------------- -------
  **Total colorectal**                                                                                                                                                                                     
  Age adjusted                                                                122        1.00 (referent)       444                 0.93 (0.76, 1.13)     69   0.95 (0.71, 1.28)   48   0.66 (0.47, 0.92)   0.025
  Multivariate adjusted[b](#t3-fn3){ref-type="fn"}                            122        1.00 (referent)       444                 1.00 (0.81, 1.23)     69   1.11 (0.82, 1.51)   48   0.76 (0.54, 1.07)   0.143
  Multivariate adjusted[c](#t3-fn4){ref-type="fn"}                            122        1.00 (referent)       444                 1.01 (0.82, 1.24)     69   1.13 (0.83, 1.54)   48   0.77 (0.55, 1.09)   0.175
  **Histopathology[c](#t3-fn4){ref-type="fn"}[,d](#t3-fn5){ref-type="fn"}**                                                                                                                                
  Adenocarcinoma                                                              113        1.00 (referent)       415                 1.03 (0.83, 1.28)     64   1.16 (0.84, 1.59)   44   0.79 (0.55, 1.13)   0.191
  **Topography[c,](#t3-fn4){ref-type="fn"}[e](#t3-fn6){ref-type="fn"}**                                                                                                                                    
  Proximal                                                                    61         1.00 (referent)       255                 1.13 (0.84, 1.51)     40   1.31 (0.86, 1.98)   26   0.84 (0.52, 1.36)   0.356
  Distal                                                                      28         1.00 (referent)       98                  0.92 (0.60, 1.44)     12   0.75 (0.37, 1.51)   10   0.63 (0.30, 1.33)   0.181
  Rectal                                                                      31         1.00 (referent)       87                  0.87 (0.57, 1.34)     15   1.12 (0.59, 2.13)   10   0.70 (0.33, 1.46)   0.602
  **Stage[c,](#t3-fn4){ref-type="fn"}[f](#t3-fn7){ref-type="fn"}**                                                                                                                                         
  I                                                                           49         1.00 (referent)       147                 0.88 (0.62, 1.23)     22   0.98 (0.58, 1.66)   17   0.74 (0.42, 1.31)   0.533
  II                                                                          27         1.00 (referent)       106                 1.09 (0.70, 1.69)     16   1.22 (0.64, 2.32)   13   0.97 (0.49, 1.93)   0.846
  III and IV                                                                  39         1.00 (referent)       168                 1.16 (0.81, 1.67)     29   1.39 (0.84, 2.30)   14   0.67 (0.36, 1.26)   0.146

Abbreviations: CI=confidence interval; NSAID=non-steroidal anti-inflammatory drug; RR=relative risk.

All estimated RRs and 95% CIs were computed using Cox proportional hazards regression models with person-years as the underlying time metric.

All multivariate models were adjusted by age, gender, race, family history of colorectal cancer, education, body mass index (kg m^2^), physical activity, smoking status, NSAID intake, history of diabetes, number of colorectal examinations up to 3 years before the start of study, hormone use (among women), alcohol intake (g per day) and study centre.

All multivariate models were adjusted by age, gender, race, family history of colorectal cancer, education, body mass index (kg m^−2^), physical activity, smoking status, NSAID intake, history of diabetes, number of colorectal examinations up to 3 years before the start of study, hormone use (among women), fruit intake (servings per day), vegetable intake (servings per day), meat intake (g per day), alcohol intake (g per day) and study centre. *P*-values for linear trends were calculated using the quintile median values. All statistical tests were two-sided and considered significant at *P*\< 0.05. All analyses were carried out using SAS software (version 9.3).

By histopathology: 636 adenocarcinoma; 31 carcinoid; 6 squamous; 10 other cases.

By topography: 382 proximal; 148 distal; 143 rectal; 10 unspecified cases.

By stage: 235 stage I; 162 stage II; 250 stage III/IV; 36 unspecified cases.
